Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Harper Hubbeling"'
Autor:
Emily Miao, Jordan E. Eichholz, Emily S. Lebow, Jessica Flynn, Zhigang Zhang, Henry Walch, Harper Hubbeling, Kathryn Beal, Nelson S. Moss, Kenny K. Yu, Alicia Meng, Daniel W. Kelly, Daniel R. Gomez, Bob T. Li, Andreas Rimner, Nikolaus Schultz, Alexander Drilon, Brandon S. Imber, Luke R.G. Pike
Publikováno v:
Lung Cancer. 178:57-65
Autor:
Harper Hubbeling, Noura Choudhury, Jessica Flynn, Zhigang Zhang, Christina Falcon, Valerie W. Rusch, Bernard J. Park, Etay Ziv, Narek Shaverdian, Daphna Y. Gelblum, Annemarie F. Shepherd, Charles B. Simone, Abraham J. Wu, Daniel R. Gomez, Alexander Drilon, Andreas Rimner
Publikováno v:
JCO Precision Oncology.
PURPOSE Local therapy prolongs progression-free survival in patients with oligometastatic non–small-cell lung cancers treated with chemotherapy. We previously reported that local therapy also prolongs survival and time to next therapy in patients o
Autor:
Satoshi Yoda, Wafa Malik, Adam Langenbucher, Justin F. Gainor, Sai-Hong Ignatius Ou, Kylie Prutisto-Chang, Ramin Sakhtemani, Jennifer L Peterson, Aaron N. Hata, Alexander Drilon, Andrew Do, Jessica J. Lin, Adam J. Schoenfeld, Viola W. Zhu, Ted William Johnson, Jochen K. Lennerz, Lecia V. Sequist, Noura J. Choudhury, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Christina Falcon, Charlotte E. Lee, Alice T. Shaw, Michael S. Lawrence, Beow Y. Yeap, Jennifer S. Temel, Harper Hubbeling
Publikováno v:
Clin Cancer Res
Purpose: Current standard initial therapy for advanced, ROS proto-oncogene 1, receptor tyrosine kinase fusion (ROS1)-positive (ROS1+) non–small cell lung cancer (NSCLC) is crizotinib or entrectinib. Lorlatinib, a next-generation anaplastic lymphoma
Autor:
Beow Y. Yeap, Jochen K. Lennerz, Harper Hubbeling, Rebecca J. Nagy, Jennifer Ackil, Jessica J. Lin, Marguerite Rooney, Aaron N. Hata, Emily Chin, Anna F. Farago, Alice T. Shaw, Justin F. Gainor, Richard B. Lanman, Ibiayi Dagogo-Jack
Publikováno v:
Clinical Cancer Research. 25:6662-6670
Purpose: Acquired resistance to next-generation ALK tyrosine kinase inhibitors (TKIs) is often driven by secondary ALK mutations. Here, we investigated utility of plasma genotyping for identifying ALK resistance mutations at relapse on next-generatio
Autor:
Jordan Eichholz, Emily Miao, Emily Lebow, Henry Walch, Jessica Flynn, Zhigang Zhang, Harper Hubbeling, Kathryn Beal, Nelson Moss, Kenny Yu, Jonathan Yang, Alicia Meng, Daniel Kelly, Thomas Boerner, Daniel Gomez, Andreas Rimner, Nikolaus Schultz, Alexander Drilon, Brandon Imber, Luke Pike
Publikováno v:
Neuro-Oncology. 24:vii3-vii3
PURPOSE Brain metastases (BM) are common in patients with anaplastic lymphoma kinase fusion-positive NSCLC (ALK+ NSCLC). We characterized the genomics of patients with ALK+ NSCLC BM treated with alectinib with or without local therapy to identify cor
Autor:
Abraham J. Wu, V. Rusch, Andreas Rimner, Bernard J. Park, Harper Hubbeling, E. Ziv, Charles B. Simone, Daniel R. Gomez, Christina Falcon, Annemarie F. Shepherd, A. Drilon, Daphna Y. Gelblum, Narek Shaverdian, Noura J. Choudhury
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 111:e438-e439
Purpose/Objective(s) Local therapy (LTX) prolongs progression-free and overall survival (OS) in patients with oligometastatic non-small cell lung cancer. We previously reported substantial LTX benefit in time to progression or next therapy (TTP/TTNT)
Autor:
William A. Mehan, Justin F. Gainor, Alice T. Shaw, Kevin S. Oh, Beow Y. Yeap, Helen A. Shih, Emily Schapira, Harper Hubbeling
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 101:624-629
Purpose Despite the emerging role of programmed cell death-1 (PD-1) pathway inhibitors for patients with advanced lung cancer, a paucity of data are available on the activity of these agents among patients with brain metastases. We investigated the o
Autor:
N.A. Wijetunga, Michael Scordo, Carla Hajj, Brandon S. Imber, Connie Lee Batlevi, Miguel-Angel Perales, Sergio Giralt, Renier J. Brentjens, Craig S. Sauter, Joachim Yahalom, Parastoo B. Dahi, Gunjan L. Shah, Jae H. Park, Harper Hubbeling, Emily S. Lebow, Emily A. Silverman, Richard J. Lin, Roni Shouval, Kathryn R. Tringale, M. Lia Palomba, Ana Alarcon Tomas
Publikováno v:
Blood. 138:1429-1429
Background: Patients with diffuse large B cell lymphoma (DLBCL) who do not achieve a complete response (CR) following CD19-targeted Chimeric Antigen Receptor T cell (CAR T) therapy are less likely to obtain durable benefit. Greater tumor burden pre-C
Autor:
Gunjan L. Shah, N. Ari Wijetunga, Craig S. Sauter, Connie Lee Batlevi, Carla Hajj, Emily A. Silverman, Renier J. Brentjens, Kathryn R. Tringale, Sergio Giralt, Emily S. Lebow, Harper Hubbeling, Roni Shouval, Joachim Yahalom, Michael Scordo, Richard J. Lin, Jae H. Park, M. Lia Palomba, Ana Alarcon Tomas, Parastoo B. Dahi, Brandon S. Imber, Miguel-Angel Perales
Publikováno v:
Blood. 138:2507-2507
Background: There is compelling rationale to use bridging radiotherapy (BRT) between leukapheresis and chimeric antigen receptor T-cell infusion for cytoreduction and palliation of relapsed/refractory B cell malignancies. There is also preclinical ev
Autor:
James S. Hardwick, Alice T. Shaw, Anna F. Farago, Aaron N. Hata, Lorin A. Ferris, Diane Tseng, Katherine Schultz, Beow Y. Yeap, Luc Friboulet, Justin F. Gainor, Satoshi Yoda, Donghui Huang, Leila Dardaei, Zofia Piotrowska, Ibiayi Dagogo-Jack, A. John Iafrate, Jessica J. Lin, Harper Hubbeling, Mari Mino-Kenudson
Publikováno v:
JCO Precision Oncology. :1-13
Purpose The ROS1 tyrosine kinase is activated through ROS1 gene rearrangements in 1% to 2% of non–small-cell lung cancers (NSCLCs), which confer sensitivity to treatment with the anaplastic lymphoma kinase (ALK)/ROS1/mesenchymal-epithelial transiti